

**Supplementary Table 3.** The risk of NAFLD defined by surrogate markers according to myosteatosis indices in the total population

Variable	Q1	Q2	Q3	Q4	P for trend
<b>HSI <math>\geq 30</math></b>					
<b>SMA/BMI</b>					
Prevalence	2,725/3,363 (81.0)	2,321/3,363 (69.0)	1,986/3,363 (59.1)	1,539/3,362 (45.8)	
Unadjusted	5.06 (4.53–5.65)	2.64 (2.39–2.92)	1.71 (1.55–1.88)	1 (ref)	<0.001
Multivariable	4.57 (3.98–5.24)	2.34 (2.07–2.64)	1.56 (1.39–1.75)	1 (ref)	<0.001
<b>NAMA/BMI</b>					
Prevalence	2,796/3,362 (83.2)	2,363/3,364 (70.2)	2,014/3,363 (59.9)	1,398/3,362 (41.6)	
Unadjusted	6.94 (6.20–7.77)	3.32 (3.00–3.67)	2.10 (1.90–2.31)	1 (ref)	<0.001
Multivariable	7.87 (6.78–9.14)	3.16 (2.78–3.58)	2.04 (1.81–2.29)	1 (ref)	<0.001
<b>NAMA/TAMA</b>					
Prevalence	2,725/3,363 (81.0)	2,338/3,363 (69.5)	2,022/3,364 (60.1)	1,486/3,362 (44.2)	
Unadjusted	5.39 (4.83–6.02)	2.88 (2.61–3.18)	1.90 (1.73–2.10)	1 (ref)	<0.001
Multivariable	5.55 (4.82–6.39)	2.76 (2.43–3.12)	1.85 (1.64–2.08)	1 (ref)	<0.001
<b>LAMA/BMI</b>					
Prevalence	1,632/3,361 (48.5)	2,042/3,364 (60.7)	2,312/3,363 (68.7)	2,586/3,363 (76.9)	
Unadjusted	0.28 (0.26–0.32)	0.46 (0.42–0.52)	0.66 (0.59–0.74)	1 (ref)	<0.001
Multivariable	0.30 (0.26–0.34)	0.45 (0.40–0.52)	0.68 (0.60–0.77)	1 (ref)	<0.001
<b>SNS <math>\geq 8</math></b>					
<b>SMA/BMI</b>					
Prevalence	1,942/3,363 (57.7)	1,387/3,363 (41.2)	997/3,363 (29.6)	681/3,362 (20.3)	
Unadjusted	5.38 (4.83–6.00)	2.76 (2.48–3.08)	1.66 (1.48–1.86)	1 (ref)	<0.001
Multivariable	4.28 (3.76–4.88)	2.41 (2.12–2.73)	1.44 (1.27–1.64)	1 (ref)	<0.001
<b>NAMA/BMI</b>					
Prevalence	2,109/3,362 (62.7)	1,383/3,364 (41.1)	966/3,363 (28.7)	549/3,362 (16.3)	
Unadjusted	8.62 (7.69–9.68)	3.58 (3.19–4.01)	2.07 (1.84–2.32)	1 (ref)	<0.001
Multivariable	7.95 (6.89–9.16)	3.23 (2.82–3.69)	1.87 (1.63–2.13)	1 (ref)	<0.001
<b>NAMA/TAMA</b>					
Prevalence	2,044/3,363 (60.8)	1,419/3,363 (42.2)	983/3,364 (29.2)	562/3,362 (16.7)	
Unadjusted	7.72 (6.89–8.65)	3.64 (3.25–4.07)	2.06 (1.83–2.31)	1 (ref)	<0.001
Multivariable	6.86 (5.98–7.88)	3.26 (2.86–3.72)	1.88 (1.65–2.15)	1 (ref)	<0.001
<b>LAMA/BMI</b>					
Prevalence	669/3,361 (19.9)	1,056/3,364 (31.4)	1,393/3,363 (41.4)	1,889/3,363 (56.2)	
Unadjusted	0.19 (0.17–0.22)	0.36 (0.32–0.39)	0.55 (0.50–0.61)	1 (ref)	<0.001
Multivariable	0.23 (0.20–0.26)	0.38 (0.34–0.42)	0.58 (0.52–0.65)	1 (ref)	<0.001

Values are presented as number (%) or odds ratio (95% confidence interval). Multivariable analysis adjusted for age, sex, smoking status, alcohol consumption, regular exercise, hypertension, diabetes, triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and alanine aminotransferase.

NAFLD, nonalcoholic fatty liver disease; HSI, hepatic steatosis index; SMA, skeletal muscle area; BMI, body mass index; NAMA, normal attenuation muscle area; TAMA, total abdominal muscle area; LAMA, low attenuation muscle area; SNS, Simple NAFLD score.